We are live on ! Find out more
OPPM

Opus Point Partners Management Portfolio holdings

AUM $55.3M
1-Year Est. Return 7.48%
This Fund
S&P 500
This Quarter Est. Return
+2.88%
1 Year Est. Return
-7.48%
3 Year Est. Return
+85.18%
5 Year Est. Return
+168.21%
10 Year Est. Return
–
AUM
$51M
AUM Growth
-$64.6M
Cap. Flow
-$49.3M
Cap. Flow %
-96.64%
Top 10 Hldgs %
55.64%
Holding
66
New
2
Increased
14
Reduced
32
Closed
15

Top Buys

Rank Stock Value
1
BIB icon
ProShares Ultra NASDAQ Biotechnology
BIB
+$3.42M
2
ACAD icon
Acadia Pharmaceuticals
ACAD
+$827K
3
KYNB
Kyntra Bio
KYNB
+$730K
4
ALXN
Alexion Pharmaceuticals
ALXN
+$513K
5
TSRO
TESARO, Inc.
TSRO
+$418K

Top Sells

Rank Stock Value
1
NKTR icon
Nektar Therapeutics
NKTR
+$5.9M
2
BMY icon
Bristol-Myers Squibb
BMY
+$5.51M
3
MRK icon
Merck
MRK
+$4.71M
4
RXDX
Ignyta, Inc.
RXDX
+$4.55M
5
AZN icon
AstraZeneca
AZN
+$4.16M

Sector Composition

Rank Sector Weight
1 Healthcare 65.24%
2 Miscellaneous 34.76%
3 Real Estate 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SCYX icon
51
SCYNEXIS
SCYX
$45.8M
$45K 0.09%
416
-417
-50% -$57.5K
AZN icon
52
AstraZeneca
AZN
$254B
– –
-60,000
Closed -$4.16M
BMY icon
53
CALL
Bristol-Myers Squibb
BMY
$131B
– –
-45,000
Closed -$2.76M
BMY icon
54
Bristol-Myers Squibb
BMY
$131B
– –
-90,000
Closed -$5.51M
GILD icon
55
CALL
Gilead Sciences
GILD
$182B
– –
-10,000
Closed -$716K
GSK icon
56
GSK
GSK
$100B
– –
-48,000
Closed -$2.13M
HRTX icon
57
Heron Therapeutics
HRTX
$59.9M
– –
-15,874
Closed -$287K
LLY icon
58
CALL
Eli Lilly
LLY
$1.01T
– –
-15,000
Closed -$1.27M
MRK icon
59
Merck
MRK
$357B
– –
-87,718
Closed -$4.71M
PFE icon
60
Pfizer
PFE
$158B
– –
-118,364
Closed -$4.07M
SAGE
61
PUT
DELISTED
Sage Therapeutics
SAGE
– –
-71,000
Closed -$11.7M
SNR
62
DELISTED
NEW SENIOR INVESTMENT GROUP INC.
SNR
– –
-41,850
Closed -$316K
ALXN
63
CALL
DELISTED
Alexion Pharmaceuticals
ALXN
– –
-35,000
Closed -$4.19M
BIVV
64
DELISTED
Bioverativ Inc. Common Stock
BIVV
– –
-6,689
Closed -$361K
JUNO
65
DELISTED
Juno Therapeutics, Inc.
JUNO
– –
-5,588
Closed -$255K
RXDX
66
DELISTED
Ignyta, Inc.
RXDX
– –
-170,500
Closed -$4.55M
1 2
3

Similar funds

KIA
Kopp Investment Advisors Bloomington, Minnesota $54.4M AUM 14.33% 1-Year Est. Return
PGA
Premia Global Advisors Coral Gables, Florida $57.9M AUM 2.91% 1-Year Est. Return
GX
Greylock XII Menlo Park, California $51.9M AUM 11.52% 1-Year Est. Return
SCG
Saban Capital Group Los Angeles, California $59.5M AUM 3.83% 1-Year Est. Return
TCMV
Technology Crossover Management VI Menlo Park, California $59.6M AUM 18.81% 1-Year Est. Return
FCM
Farmstead Capital Management Ridgewood, New Jersey $49M AUM 10.57% 1-Year Est. Return
DP
DW Partners New York $62.3M AUM 25.52% 1-Year Est. Return
SAM
Sheffield Asset Management Chicago, Illinois $48.1M AUM 12.96% 1-Year Est. Return

Opus Point Partners Management's Q1 2018 Portfolio in Review

As of Q1 2018, Opus Point Partners Management held 66 positions worth $51M, down 56% from $116M the previous quarter. Its ten largest holdings account for 56% of the portfolio.

Opus Point Partners Management withdrew a net $49.3M in Q1 2018, closing 15 positions and reducing 32 holdings. Its most notable exit was Bristol-Myers Squibb, an estimated $5.51M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 65% of assets, down from 67% a quarter earlier, followed by Miscellaneous and Real Estate.

Against the trend, Opus Point Partners Management opened a new position in bluebird bio worth $226K.

  • Opus Point Partners Management's largest Q1 2018 buy was bluebird bio: 102 shares worth $226K.
  • Opus Point Partners Management added most to ProShares Ultra NASDAQ Biotechnology in Q1 2018, an estimated $3.42M increase.
  • Opus Point Partners Management's biggest Q1 2018 reduction was Nektar Therapeutics, cutting an estimated $5.9M.
  • Opus Point Partners Management fully exited Bristol-Myers Squibb in Q1 2018, selling an estimated $5.51M.
  • Opus Point Partners Management's ten largest holdings make up 56% of its $51M portfolio in Q1 2018.
  • Opus Point Partners Management opened 2 new positions and closed 15 in Q1 2018.
  • Opus Point Partners Management's portfolio value fell 56% quarter-over-quarter to $51M.

Based on Opus Point Partners Management's 13F filing for Q1 2018, filed 15 May 2018.